Icenticaftor

Icenticaftor (QBW251) is an orally active CFTR channel potentiator, with EC50s of 79 nM and 497 nM for F508del and G551D CFTR, respectively. Icenticaftor can be used for chronic obstructive pulmonary disease (COPD) and cystic fibrosis research[1].

Product Specifications

CAS Number

[1334546-77-8]

Product Name Alternative

QBW251

UNSPSC

12352005

Hazard Statement

H315, H319

Target

CFTR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/icenticaftor.html

Purity

99.66

Solubility

DMSO : 150 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=NC(OC)=C(C(F)(F)F)C=C1N)NC[C@](C)(O)C(F)(F)F

Molecular Formula

C12H13F6N3O3

Molecular Weight

361.24

Precautions

H315, H319

References & Citations

[1]Darren Le Grand, et al. Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease. J Med Chem. 2021 Jun 10;64 (11) :7241-7260.|[2]Steven M Rowe, et al. Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial. Int J Chron Obstruct Pulmon Dis. 2020 Oct 5;15:2399-2409.